Aceragen Alternatives & Competitors

12 companies similar to Aceragen — Aceragen is a rare disease company striving to restore a better life for patient...

Intercept Pharmaceuticals

Our mission is to build a healthier tomorrow for patients with rare and serious liver dise...

376 Post-IPO Debt $970.05M

Morristown, United States

Biotechnology Health Care +1

Lumos Pharma

Transforming Lives with Rare Focus

47 Series B $53.50M

Austin, United States

Biopharma Biotechnology +2

Compare

Eloxx Pharmaceuticals

Clinical-stage biopharma company developing novel RNA-modulating drug candidates to treat...

12 IPO $63.29M

Watertown, United States

AllStripes (now PicnicHealth)

Unlocking new treatments for people with rare disease

8 Acquired $67.10M

San Francisco, United Sta...

Big Data Biotechnology +3

Track all Aceragen competitors

Get real-time alerts when any of these companies raise funding, hire, or show growth signals.

See how it works

Acer Therapeutics Inc.

Focused on the acquisition, development & commercialization of therapies for serious rare...

16 Post-IPO Debt $116.95M

Newton, United States

Biotechnology Health and Wellness +1

Neurotrope Inc.

Developing a new approach to combating Alzheimer's disease and other neurodegenerative dis...

3 Series A $21.90M

New York, United States

Biotechnology Health Care

Lexicon Pharmaceuticals, Inc.

At Lexicon, We Pioneer Medicines that Transform Patients' Lives

283 Post-IPO Equity $813.62M

The Woodlands, United Sta...

Biotechnology Pharmaceutical +1

Healx

AI-powered and patient-inspired. We accelerate the discovery and development of rare dis...

71 Growth $136.42M

Cambridge, United Kingdom

AI Biopharma +3

Auxesia Orion

Tech-enabled patient-centric therapeutic management for orphan diseases where drugs are on...

3 Venture round

Santa Clara, United State...

Health Care Information Technology +1

Dynacure

Dynacure develops new treatments for orphan disorders, focusing on CNM through Dyn101 prog...

Series C $100.27M

Illkirch-graffenstaden, F...

Biotechnology Health Care +2

VYNE Therapeutics Inc.

For every therapeutic challenge, we question traditional assumptions and find better solut...

52 Post-IPO Equity $297.84M

Bridgewater, United State...

Health Care Health and Wellness +1

Wilson Therapeutics

Innovative pathways to treat rare conditions and enhance patient lives

Post-IPO Equity $284.00M

Biotechnology Health Care +1

About Aceragen

Aceragen is a rare disease biopharmaceutical company founded in 2021 with a clear mission to address rare, orphan diseases with no available treatment. Their slogan, "Aceragen is a rare disease company striving to restore a better life for patients and families," reflects their commitment to improving the lives of pati...

Taxonomy

Rare Diseases, Orphan Diseases, Biopharmaceutical, Therapeutic Treatments, Drug Development, Patient-centric, Community Awareness, Regulatory Outreach, Novel Therapies, Patient Advocacy

Frequently Asked Questions

Companies similar to Aceragen include Intercept Pharmaceuticals, Lumos Pharma, Eloxx Pharmaceuticals, AllStripes (now PicnicHealth), Acer Therapeutics Inc.. They work in Biotechnology and Health Care and share Aceragen's focus on drug development, biopharmaceutical and rare diseases.

Bounce Watch lists 12 companies that share Aceragen's industries and are closest to it in business tags, services, target customers, business model and size.

Don't just read about them. Follow them.

BounceWatch watches Aceragen and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.

See how it works

Explore Related

Aceragen Profile Intercept Pharmaceuticals Alternatives Lumos Pharma Alternatives Eloxx Pharmaceuticals Alternatives All Companies All Signals Trend Reports

Compiled from the BounceWatch company index. We last looked at Aceragen on 12 Sep 2024. The 12 companies listed here were last checked between 26 Jul 2024 and 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.